bpc-157 human clinical trials evidence review 2024 2025 Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key: A Special Beneficial Pleiotropic Effect Controlling and Modulating Angiogenesis and the NO-System BPC-157 as an Investigational Peptide

Marketing Authorization Holder GERDA LABORATORIES 24 RUE ERLANGER 75016 PARIS Operator of the marketing authorization GERDA LABORATORIES 24 RUE ERLANGER 75016 PARIS Maker DELPHARM TOURS LA BARAUDIERE 37170 CHAMBRAY LES TOURS or HAUPT PHARMA LIVRON 1 STREET COUNTY SINARD 26250 LIVRON-SUR-DROME Names of the drug in the member states of the European Economic Area Not applicable

-Susan Yep hCGer 4: I did use the mic/lipo during the shots and afterwards

Severe GI reactions (peptic ulcer, GI bleeding, and GI perforation) occurred in 0.4% to 4.6% of patients without a history of a peptic ulcer or bleed and in 2.1% to 15.4% of patients with a history of a peptic ulcer or bleed

Reconstituted solution Once mixed with bacteriostatic water , refrigerate at 2-8C

Dangers and uncertainties still loom